Day 1|  Day 2 |  Day 3 | Download Brochure 

Thursday, February 23

 

CLINICAL USE OF CIRCULATING TUMOR CELLS

8:30 am Chairperson’s Remarks

Michail Ignatiadis, M.D., Ph.D., Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium

8:35 Bioengineering and Clinical Applications of Microfluidic Circulating Tumor Cell Chip

Shyamala Maheswaran, Ph.D., Associate Professor, Surgery & Molecular Biology, Harvard Medical School

This presentation will describe the engineering design and clinical validation of the microfluidic CTC-chip.

9:05 Detection of Viable Circulating Tumor Cells (CTC) in Solid Tumors Using the EPISPOT Assay

Catherine Alix-Panabières, Ph.D., Professor Assistant, Laboratory of Rare Human Circulating Cells, Institute of Research in Biotherapy, University Medical Center of Montpellier

The EPISPOT assay is combined to a depletion of CD45+ hematopoietic cells, avoiding the positive enrichment based only on EpCAM expression on the CTC. We detected only viable CTC with specific phenotypes and applied it to breast, prostate and colon cancer. Due to the heterogeneity among CTC, several sub-populations may secrete/shed/release different proteins (i.e., a stem cell growth factor to facilitate their outgrowth in distant organs).

9:35 HER2 Expression on CTCs/DTCs in Breast Cancer: Is there Any Role in Clinical Practice?

Michail Ignatiadis, M.D., Ph.D., Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium

Data for HER2 expression on CTCs/DTCs and matched primary tumors in breast cancer will be reviewed. Results from an international ring study to interrogate inter-reader variability in CTC and HER2-positive CTC detection using the CellSearch technology in early breast cancer will be presented. Finally, an update on ongoing trials testing the clinical utility of HER2 expression on CTCs will be provided.

Sponsored by10:05 The Development of a Circulating Melanoma Cell AssayM. Craig Miller, Manager, Clinical Sciences, Veridex, LLC • Provide an overview of the development and validation of this new Research Use Only assay which utilizes the CellSearch® system for the isolation, enumeration, and characterization of circulating melanoma cells. 
• Present a few examples of how this new standardized assay for CMCs may help you in your research and drug development programs for metastatic melanoma.


10:20 Coffee Break 

NOVEL TECHNOLOGIES SESSION

11:00 Technology “Show ‘N Tell” Demonstration in the Foyer

Membrane Microfilter Device for Tumor Cell Capture

Richard Cote, M.D., FRCPath, Professor and Chair, Department of Pathology; Director, University of Miami Biomedical Nanoscience Institute, University of Miami Miller School of Medicine

Pinched Flow Coupled Shear-Modulated Inertial Microfluidics for High-Throughput Rare Blood Cell Separation

Chwee Teck Lim, Ph.D., Principal Investigator, Mechanobiology Institute; Faculty Fellow, Singapore-MIT Alliance for Research & Technology (SMART); Professor, Division of Bioengineering & Department of Mechanical Engineering, National University of Singapore

Isolation of Circulating Tumor Cells Using High Precision Microfilters

Cha-Mei Tang, Sc.D., President and CEO, Creatv MicroTech, Inc.

Immunomagnetic Nano-Screening Chip for Circulating Tumor Cells

John X.J. Zhang, Ph.D., Associate Professor, Biomedical Engineering, The University of Texas at Austin

Multi-Orifice Flow Fractionation (MOFF) and Dielectrophoresis (DEP) Separation of CTCs

Hyo-Il Jung, Ph.D. (Cantab), Associate Professor, School of Mechanical Engineering, Yonsei University

Dielectrophoresis (DEP) in a Microfluidics Platform to Study Isolation and Enrichment of Cancer Cell

Guiren Wang, Ph.D., Assistant Professor, Department of Mechanical Engineering & Biomedical Engineering Program, University of South Carolina

ScreenCell Filtration Devices for Isolation of Circulating Rare Cells

Yvon E. Cayre, M.D., D.Sci., Professor, Pierre and Marie Curie University; CSO, ScreenCell

A Mesofluidic Multiplex Immunosensor for Detection of  CTC

P.L. Tran, Ph.D., Biomicrosystems and Health, CyToCap

Automated Genotyping of Circulating Tumor Cells

Chengxun Liu, Ph.D., Senior Researcher, Functional Nanosystems Group, imec

 

12:30 Luncheon Presentation (Sponsorship Opportunity Available) or Lunch on Your Own

 

FUNDING AND REGULATION OF CTCS

1:45 Chairperson’s Remarks

1:50 Grants Available through SBIR

Xing-Jian Lou, Ph.D, Program Director, SBIR Development Center, National Cancer Institute

2:10 NCI/NIH Funding Opportunities

Avraham Rasooly, Ph.D., Chief, Disparities Research Branch, Center to Reduce Cancer Health Disparities, National Cancer Institute
 

FUTURE TRENDS IN CTC DIAGNOSTICS

2:25 Chairperson’s Remarks

Steven A. Soper, Ph.D., University of North Carolina, Chapel Hill and Dave Hoon, M.Sc., Ph.D., John Wayne Cancer Institute

2:35 Future Trends in Clinical Development

Dave Hoon, M.Sc., Ph.D., Director, Molecular Oncology, John Wayne Cancer Institute

2:55 Future Trends in Technology Development

Steven A. Soper, Ph.D., William H. Pryor Emeritus Professor, Department of Biomedical Engineering and Chemistry; Director, Center for Biomodular System, University of North Carolina, Chapel Hill; and WCU Scholar, UNIST, S. Korea

 

3:30 Closing Remarks

3:35 Close of Conference

Day 1|  Day 2 |  Day 3 | Download Brochure